AI Article Synopsis
- Chronic myeloid leukemia (CML) is characterized by an increase in immature granulocytes and is commonly linked to the Philadelphia chromosome, affecting 95% of cases.
- Some CML patients (3.1-9.1%) may also experience extramedullary proliferation in areas like skin or lymph nodes, leading to conditions like myeloid sarcoma (MS), which is associated with immature myeloid cells.
- This report discusses an elderly female patient with CML in the chronic phase who presented with myeloid sarcoma in her right parotid gland during treatment with imatinib.
Article Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by immature granulocytes in the peripheral blood and bone marrow. In 95% of cases, it is always associated with the presence of the Philadelphia chromosome, which is characterized by the presence of reciprocal translocation between chromosomes 9 and 22. However, 3.1-9.1% of patients also have an extramedullary proliferation of skin, lymph nodes, bone, or central nervous system (CNS), which could be either myeloid, lymphocytic, or mixed lineage in origin. An extramedullary myelogenous neoplasm termed myeloid sarcoma (MS) can originate from myeloblasts or immature myeloid cells. Due to the green, gross appearance caused by the myeloperoxidase enzyme in immature myeloid cells, it is also known as chloroma. According to WHO guidelines, it is a tumor composed of myeloid blasts, mature or immature. Here we report an old female patient with CML - chronic phase who came for imatinib therapy and presented as MS in the right parotid gland.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848683 | PMC |
| http://dx.doi.org/10.7759/cureus.32691 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!